Application No. 09/972,425 Attorney's Docket No. 0330537075

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)		0, = 3, 3
Kenneth C. Cundy, et al.) Group Art Unit:	1614	
Application No.: 09/972,425) Examiner:	Unassigned	RECEIVED
Filed: October 5, 2001 For: Bile-Acid Derived Compounds for)))		AUG 2 8 2002
Providing Sustained Systemic Concentrations of Drugs After Oral Administration)))	TI	ECH CENTER 1600/290(

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT TRANSMITTAL LETTER

Assistant Commissioner for Patents Washington, D.C. 20231
Sir:

4

Enclosed is an Information Disclosure Statement and accompanying form PTO-1449 for the above-identified patent application.

[x]	No additional fee for submission of an IDS is required.			
[]	The fee of IDS as set forth in 37 C.F.R. § 1.17(p) is also enclosed.			
[]	A certification under 37 C.F.R. § 1.97(e) is also enclosed.			
[]	A certification under 37 C.F.R. § 1.97(e), and the fee of IDS as set forth in 37 C.F.R. § 1.17(p) are also enclosed.			
[]	Charge \$ to Deposit Account No. 02-4800 for the fee due.			
[]	A check in the amount of \$ is enclosed for the fee due.			
The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R				

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

P.O. Box 1404 Alexandria, Virginia 22313-1404

Tel: (650) 622-2300 Date: 8-26-02 Gerald F. Swiss Registration No. 30,113



Application No. 09/972,425 Attorney's Docket No. 033053-025

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

in re Patent Application of)	RECEIVED
Kenneth C. Cundy, et al.) Oroup Art Unit: 1614	AUG 2 8 2002
Application No.: 09/972,425) Examiner: Unassigned	TECH CENTER 1600/290
Filed: October 5, 2001)	
For: Bile-Acid Derived Compounds For Providing Sustained Systemic Concentrations of Drugs After Oral Administration))))	

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98. Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited below is enclosed:

U.S. Patents:

4,508,728	Nagai et al.	4/2/85
4,908,353	Yamamoto et al.	3/13/90
5,094,848	Brixner	3/10/92
5,110,797	Ienaga et al.	5/5/92
6,051,683	Deigin et al.	4/18/2000

Foreign Patents:

SU 285929 1/13/71

Soviet Union

Information Disclosure Statement Application No. 09/972,425 Attorney's Docket No. <u>033053-025</u>

Page 2

•

The documents are being submitted within 3 months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later, therefore no fee or certification is required under 37 C.F.R.

§ 1.97(b).

I, the undersigned, hereby state that each item of information contained in this Information Disclosure Statement was first cited in a communication received from the US/RO acting as the search authority for the equivalent PCT application (copy of ISR is enclosed herewith). Applicants submit that this constitutes a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

To assist the Examiner, the documents are also listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: _*__*

Gerald F. Swiss

Registration No. 30,133

P.O. Box 1404 Arlington, VA 22313-1404

Tel: (650) 622-2300

Date: 8-26-02